期刊文献+

阿卡波糖+生活方式干预治疗糖调节受损的疗效观察 被引量:2

下载PDF
导出
摘要 目的观察阿卡波糖+生活方式干预治疗糖调节受损(IGR)患者的疗效。方法将142例IGR患者随机分为观察组与对照组2组,每组71例。对照组给予生活方式干预治疗,观察组给予生活方式+阿卡波糖干预治疗,治疗1年后,观察2组的临床疗效;比较2组干预治疗前后体质量指数(BMI)、腰臀比、空腹血糖(FPG)、糖耐量试验(OGTT)后2 h血糖(OGTT-2h PG)、总胆固醇(TC)、三酰甘油(TG)、空腹胰岛素(FINS)、OGTT实验后2 h胰岛素(OGTT-2 h INS)、胰岛素抵抗指数(Homa IR)、胰岛素敏感指数(ISI)及肝肾功能的变化。结果对照组与观察组糖尿病年转化率分别为8.4%、4.2%,正常葡萄糖耐量(NGT)逆转率分别为16.9%、71.8%,2组相比,差异均有统计学意义(P<0.05)。观察组干预治疗后FPG、OGTT-2h PG、TC、TG、FINS、OGTT-2h INS、ISI及HomaIR均明显下降,与治疗前及对照组治疗后相比,差异均有统计学意义(P<0.05)。结论对于IGR给予生活方式干预的同时辅以阿卡波糖干预是一种更积极、更有效,且安全、依从性好的措施。阿卡波糖不仅对单纯性糖耐量受损(I-IGT)有效,对单纯性空腹血糖异常(I-IFG)、混合性糖调节受损(CGI)也有效,CGI较其它两亚型更易转为糖尿病。
出处 《实用临床医学(江西)》 CAS 2010年第8期35-36,共2页 Practical Clinical Medicine
  • 相关文献

参考文献4

二级参考文献47

  • 1The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Repot of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 1997, 20: 1183- 1197.
  • 2Feata A D, Agostino R Jr, Hanley AJ, et al. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes, 2004,53: 1549-1555.
  • 3Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabet Med, 2002,19:708-723.
  • 4Choi KM, Lee J, Kim DR, et al. Comparison of ADA and WHO criteria for the diagnosis of diabetes in elderly Koreans. Diabet Med, 2002,19:853-857.
  • 5The DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and ADA diagnostic criteria. Lancet, 1999,354: 617-621.
  • 6Jia WP, Pang C, Chen L, et al. Epidemiological Characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up in Shanghai urban communities. Diabetologia, 2007,50:286- 292.
  • 7Abdul-Ghani MA, Tfipathy D, Jenckinson C, et al. Insulin secretion and insulin action in subjects with impaired fasting glucose and impaired tolerance : results from the Veterans Administration Genetic Epidemiology Study(VEGAS). Diabetes, 2006,22:345-356.
  • 8Tripathy D, Carlesson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes, 2000,49:975-980.
  • 9Meyer C, Pimenta W, Woerle HJ, et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care, 2006,22 : 1909-1914.
  • 10Weyer C, Bogardus C, Pratley RE: Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes, 1999,48:2193-2203.

共引文献83

同被引文献40

  • 1王先令,陆菊明,潘长玉.不同糖耐量水平者血清C反应蛋白水平及阿卡波糖干预的影响[J].中华内分泌代谢杂志,2003,19(4):254-256. 被引量:43
  • 2Kitaoto H. Efficacy of combination therapy of alpha-gluc- osidase inhibitor and insulin sensitizer in patients with type 2 diabetes[J]. Nippon Rinsho, 2002, 60 (Suppl 9) : 464.
  • 3Chiasson JL, Josse RG, Leiter LA, et al. The effect ofac- arbose on insulin sensitivity in subjects with impaired glu- cose tolerance[J]. Diabetes Care, 1996,19(11) :1 190.
  • 4Nijpels G, Boorsma W, Dekker JM, et aL A study of the effects of acarbose on glucose metabolism in patients pre- disposed to developing diabetes: the Dutch acarbose inter- vention study in persons with impaired glucose tolerance (DAISI) [J]. Diabetes Metab Res Rev, 2008,24 (8) : 611.
  • 5Pan CY, Gao Y, Chen JW, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance[J]. Dia- betes Research and Clinical Practice, 2003, 61 (3) : 183.
  • 6Laube H, Lima T, Heyen P. The effect of aearbose on in- sulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance[J]. Exp Clin Endocrinol Diabetes, 1998, 106(3) : 231.
  • 7Chang AM, Smith M J, Bloem C J, et al. Effect of lower- ing postprandial hyperglycemia on insulin secretion in old- er people with impaired glucose tolerance[J]. American Journal of Physiology Endocrinology and Metabolism, 2004,287(5) :906.
  • 8莫一丽.阿卡波糖对糖耐量异常的干预研究[J].医药前沿,2013(10):194.
  • 9Pedersen TR, Olsson AG, Faergeman O, et al. Lipopro- tein changes and reduction in the incidence of major coro- nary heart disease events in the scandinavian simvastatin survival study(4S)[J]. Atheroscler Suppl, 2004,5 (3) : 99.
  • 10王晓华.心血管疾病患者62例相关危险因素分析[J].第四军医大学学报,2008,29(7):595-595. 被引量:4

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部